CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Settings

Subject: search.filters.subject.dengue

Search Results

Now showing 1 - 4 of 4
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    EFFECTIVENESS AND SAFETY OF THE TETRAVALENT TAK-003 DENGUE VACCINE: A SYSTEMATIC REVIEW
    (2024)
    Ramos-rojas José
    ;
    Bengolea, Agustin
    ;
    Scigliano, Clara
    ;
    Rada, Gabriel  
    ;
    Catalano Hugo N.
      1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    EFFECTIVENESS AND SAFETY OF THE TETRAVALENT TAK-003 DENGUE VACCINE: A SYSTEMATIC REVIEW
    (2024-07-01)
    Bengolea, Agustín
    ;
    Scigliano, Clara
    ;
    Ramos-Rojas, Jose T.
    ;
    Rada, Gabriel  
    ;
    Catalano, Hugo N.
    In Argentina, the dengue virus has experienced an increase in recent years. This study aims to conduct a systematic review to evaluate the effectiveness and safety of the TAK-003 tetravalent dengue vaccine in this context. A systematic review of randomized controlled trials comparing the effectiveness and safety of the vaccine with placebo in the general population was conducted. The search was carried out in Epistemonikos, and two researchers independently assessed the studies. Risk of bias was evaluated using the Cochrane Rob 2 tool. A meta-analysis of the results was performed, and the certainty of evidence was assessed using the GRADE methodology. We concluded, with high certainty of evidence, that the tetravalent dengue vaccine reduces severe infections (RR 0.17, 95% CI 0.12 to 0.24) and infections by the dengue virus (RR 0.40, 95% CI 0.36 to 0.45) in a population ≤17 years. The vaccine may not increase the risk of serious adverse events, although it is important to note the low certainty of evidence (RR 1.04, 95% CI: 0.69-1.55). The use of the tetravalent dengue vaccine decreases the risk of severe and non-severe dengue infections in this population. However, there is low certainty of evidence regarding the vaccine’s safety. The decision to vaccinate should consider the magnitude of benefits relative to the risk of infection.
      3Scopus© Citations 4
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      2Scopus© Citations 38
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Rickettsial infections: A blind spot in our view of neglected tropical diseases
    (2021)
    Jeanne Salje
    ;
    WEITZEL, THOMAS  
    ;
    Paul N. Newton
    ;
    George M. Varghese
    ;
    Nicholas Day
    <jats:p>Rickettsial diseases are a group of vector-borne bacterial infections that cause acute febrile illness with potentially severe or fatal complications. These vector-borne diseases are prevalent in tropical and subtropical regions worldwide and disproportionately affect poorer communities but are scientifically underrecognized. Despite this, they are not included in the World Health Organization’s list of neglected tropical diseases nor were they mentioned in Peter Hotez’s recent reflections on “What constitutes a neglected tropical disease?” in <jats:italic>PLOS Neglected Tropical Diseases</jats:italic> [1]. Here we present the case that rickettsial infections, as an overlooked cause of morbidity, mortality, and economic losses in marginalized populations, should be recognized as neglected tropical diseases. We describe how this oversight is the result of a number of factors and how it negatively impacts patient outcomes. We then propose measures to address the neglect of rickettsial infections in both scientific research and public health interventions.</jats:p>
    Scopus© Citations 44  1